Molnupiravir (Lagevrio) is an oral antiviral for treating patients with COVID-19 in the community.

Access criteria are the same as for nirmatrelvir/ritonavir (Paxlovid). Molnupiravir should only be used where nirmatrelvir/ritonavir is clinically inappropriate, as trial data suggest molnupiravir is much less effective. Read our article for details.

Since 1 April 2022, the oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) has been listed on the Pharmaceutical Schedule for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria and to comprehensive drug interaction guidance.